Efficacy of second- and third-line chemotherapy after
chemotherapy with platinum doublet and immunotherapy in
non-small cell lung cancer: a descriptive study

J 2025

Efficacy of second- and third-line chemotherapy after chemotherapy with platinum doublet and immunotherapy in non-small cell lung cancer: a descriptive study

SVATON, Martin; Miloslav MAREL; Ondřej VENCLÍČEK; Juraj KULTAN; Marketa CERNOVSKA et al.

Základní údaje

Originální název

Efficacy of second- and third-line chemotherapy after chemotherapy with platinum doublet and immunotherapy in non-small cell lung cancer: a descriptive study

Autoři

SVATON, Martin; Miloslav MAREL; Ondřej VENCLÍČEK; Juraj KULTAN; Marketa CERNOVSKA; Michal HRNCIARIK; Jana KREJCI; Karel ODRAZKA a Petr DOMECKY

Vydání

TRANSLATIONAL CANCER RESEARCH, HONG KONG, AME PUBL CO, 2025, 2218-676X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Čína

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.700 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00142545

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Non-small cell lung cancer (NSCLC); second-line chemotherapy; third-line chemotherapy; chemoimmunotherapy

Štítky

14110215, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 11. 2025 12:59, Mgr. Tereza Miškechová

Anotace

V originále

Background: The efficacy of second-line chemotherapy with pemetrexed or docetaxel was evaluated in phase III clinical trials only after prior treatment with a platinum doublet in non-small cell lung cancer. The effectiveness of second-line chemotherapy after previous chemotherapy and immunotherapy is not well known. The effectiveness of third-line chemotherapy is not practically proven in this sense. The aim of this retrospective study was therefore to assess the effectiveness of second-and third-line chemotherapy in patients pretreated with chemotherapy with platinum doublet and immunotherapy based on retrospective data. Methods: Patients from the Czech Lung Cancer Focus (LUCAS) lung cancer registry who were pretreated with chemotherapy and immunotherapy were evaluated. Time on treatment (ToT) and overall survival (OS) with second-and third-line chemotherapy were evaluated using Kaplan-Meier method. Results: One hundred and fourteen patients treated with second-line chemotherapy were evaluated. Their ToT reached a median of 2.9 [95% confidence interval (CI): 2.4-4.7] months and OS a median of 7.2 (95% CI: 6.1-11.2) months. Twenty-two patients treated with third-line chemotherapy were evaluated. Their ToT reached a median of 5.1 (95% CI: 1.4-NA) months and OS a median of 13.8 (95% CI: 6.1-NA) months. Conclusions: The efficacy of second-line chemotherapy in our group of patients (pretreated with chemotherapy and immunotherapy) was comparable with registration studies for second-line chemotherapy. In a selected population, even third-line chemotherapy can be effective.

Citovat

SVATON, Martin; Miloslav MAREL; Ondřej VENCLÍČEK; Juraj KULTAN; Marketa CERNOVSKA; Michal HRNCIARIK; Jana KREJCI; Karel ODRAZKA a Petr DOMECKY. Efficacy of second- and third-line chemotherapy after chemotherapy with platinum doublet and immunotherapy in non-small cell lung cancer: a descriptive study. TRANSLATIONAL CANCER RESEARCH. HONG KONG: AME PUBL CO, 2025, roč. 14, č. 7, s. 4348-4356. ISSN 2218-676X. Dostupné z: https://doi.org/10.21037/tcr-2024-2555.

@article{2532582,
   author = {Svaton, Martin and Marel, Miloslav and Venclíček, Ondřej and Kultan, Juraj and Cernovska, Marketa and Hrnciarik, Michal and Krejci, Jana and Odrazka, Karel and Domecky, Petr},
   article_location = {HONG KONG},
   article_number = {7},
   doi = {https://doi.org/10.21037/tcr-2024-2555},
   keywords = {Non-small cell lung cancer (NSCLC); second-line chemotherapy; third-line chemotherapy; chemoimmunotherapy},
   language = {eng},
   issn = {2218-676X},
   journal = {TRANSLATIONAL CANCER RESEARCH},
   title = {Efficacy of second- and third-line chemotherapy after chemotherapy with platinum doublet and immunotherapy in non-small cell lung cancer: a descriptive study},
   url = {https://tcr.amegroups.org/article/view/103117/html},
   volume = {14},
   year = {2025}
}

TY  - JOUR
ID  - 2532582
AU  - Svaton, Martin - Marel, Miloslav - Venclíček, Ondřej - Kultan, Juraj - Cernovska, Marketa - Hrnciarik, Michal - Krejci, Jana - Odrazka, Karel - Domecky, Petr
PY  - 2025
TI  - Efficacy of second- and third-line chemotherapy after chemotherapy with platinum doublet and immunotherapy in non-small cell lung cancer: a descriptive study
JF  - TRANSLATIONAL CANCER RESEARCH
VL  - 14
IS  - 7
SP  - 4348-4356
EP  - 4348-4356
PB  - AME PUBL CO
SN  - 2218676X
KW  - Non-small cell lung cancer (NSCLC)
KW  - second-line chemotherapy
KW  - third-line chemotherapy
KW  - chemoimmunotherapy
UR  - https://tcr.amegroups.org/article/view/103117/html
N2  - Background: The efficacy of second-line chemotherapy with pemetrexed or docetaxel was evaluated in phase III clinical trials only after prior treatment with a platinum doublet in non-small cell lung cancer. The effectiveness of second-line chemotherapy after previous chemotherapy and immunotherapy is not well known. The effectiveness of third-line chemotherapy is not practically proven in this sense. The aim of this retrospective study was therefore to assess the effectiveness of second-and third-line chemotherapy in patients pretreated with chemotherapy with platinum doublet and immunotherapy based on retrospective data. Methods: Patients from the Czech Lung Cancer Focus (LUCAS) lung cancer registry who were pretreated with chemotherapy and immunotherapy were evaluated. Time on treatment (ToT) and overall survival (OS) with second-and third-line chemotherapy were evaluated using Kaplan-Meier method. Results: One hundred and fourteen patients treated with second-line chemotherapy were evaluated. Their ToT reached a median of 2.9 [95% confidence interval (CI): 2.4-4.7] months and OS a median of 7.2 (95% CI: 6.1-11.2) months. Twenty-two patients treated with third-line chemotherapy were evaluated. Their ToT reached a median of 5.1 (95% CI: 1.4-NA) months and OS a median of 13.8 (95% CI: 6.1-NA) months. Conclusions: The efficacy of second-line chemotherapy in our group of patients (pretreated with chemotherapy and immunotherapy) was comparable with registration studies for second-line chemotherapy. In a selected population, even third-line chemotherapy can be effective.
ER  -

SVATON, Martin; Miloslav MAREL; Ondřej VENCLÍČEK; Juraj KULTAN; Marketa CERNOVSKA; Michal HRNCIARIK; Jana KREJCI; Karel ODRAZKA a Petr DOMECKY. Efficacy of second- and third-line chemotherapy after chemotherapy with platinum doublet and immunotherapy in non-small cell lung cancer: a descriptive study. \textit{TRANSLATIONAL CANCER RESEARCH}. HONG KONG: AME PUBL CO, 2025, roč.~14, č.~7, s.~4348-4356. ISSN~2218-676X. Dostupné z: https://doi.org/10.21037/tcr-2024-2555.

Přehled o publikaci